Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company

Sandoz Becomes Independent After Spin-Off from Novartis

Fineline Cube Oct 8, 2023

Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...

Company Deals

Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio

Fineline Cube Oct 8, 2023

Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...

Company Drug

Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease

Fineline Cube Oct 8, 2023

Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...

Policy / Regulatory

NMPA and NHC Tighten Regulations on Etomidate and Modafinil

Fineline Cube Oct 8, 2023

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...

Company Deals

Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing

Fineline Cube Oct 8, 2023

Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...

Company

Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees

Fineline Cube Oct 8, 2023

US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...

Company Deals

Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine

Fineline Cube Oct 7, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...

Company Drug

Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results

Fineline Cube Oct 7, 2023

Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...

Company Deals

Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million

Fineline Cube Oct 7, 2023

Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...

Company Deals

PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development

Fineline Cube Oct 7, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...

Company Deals

Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection

Fineline Cube Oct 7, 2023

Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...

Policy / Regulatory

Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices

Fineline Cube Oct 7, 2023

The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...

Deals Medical Device

Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio

Fineline Cube Oct 7, 2023

US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...

Company Deals

Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation

Fineline Cube Oct 7, 2023

The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...

Company Drug

Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy

Fineline Cube Oct 7, 2023

Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...

Company Drug

Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine

Fineline Cube Oct 7, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

Fineline Cube Oct 7, 2023

Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...

Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Posts pagination

1 … 513 514 515 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.